Catalyst Biosciences, Inc. News Releases http://ir.catalystbiosciences.com/ Catalyst Biosciences, Inc. News Releases en Catalyst Biosciences to Present at the Jefferies 2019 Global Healthcare Conference http://ir.catalystbiosciences.com/news-releases/news-release-details/catalyst-biosciences-present-jefferies-2019-global-healthcare SOUTH SAN FRANCISCO, Calif. , May 28, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst Biosciences , will present a corporate overview at the Jefferies 2019 Global Healthcare Conference at Tue, 28 May 2019 08:00:00 -0400 Catalyst Biosciences, Inc. News Releases 12146 Catalyst Biosciences Reports First Quarter 2019 Operating & Financial Results and Provides a Corporate Update http://ir.catalystbiosciences.com/news-releases/news-release-details/catalyst-biosciences-reports-first-quarter-2019-operating Final MarzAA Phase 2 data to be presented at upcoming International Society for Thrombosis & Hemostasis (ISTH) meeting in July 2019 MarzAA Orphan Drug Designation received from the European Commission Initiated DalcA Phase 2b Trial for the Treatment of Hemophilia B SOUTH SAN FRANCISCO, Calif. Thu, 02 May 2019 08:00:00 -0400 Catalyst Biosciences, Inc. News Releases 12101 Catalyst Biosciences & Mosaic Biosciences Present Preclinical Data on Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration http://ir.catalystbiosciences.com/news-releases/news-release-details/catalyst-biosciences-mosaic-biosciences-present-preclinical-data A single intravitreal injection of 125 μg CB 2782-PEG achieved complete, rapid and sustained pharmacodynamic inhibition (>99%) of complement factor 3 (C3) in non-human primates (NHP), supporting dosing three to four times a year Data support CB 2782-PEG’s potential as a best-in-class anti-C3 ocular Mon, 29 Apr 2019 08:05:00 -0400 Catalyst Biosciences, Inc. News Releases 12096 Catalyst Biosciences to Present at The Needham & Company 18th Annual Healthcare Conference http://ir.catalystbiosciences.com/news-releases/news-release-details/catalyst-biosciences-present-needham-company-18th-annual SOUTH SAN FRANCISCO, Calif. , April 03, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences , Inc. (NASDAQ:CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer, will present a corporate overview at the Needham & Company 18th Annual Healthcare Conference at 12:50 p.m. Wed, 03 Apr 2019 08:00:00 -0400 Catalyst Biosciences, Inc. News Releases 12066 Catalyst Biosciences Initiates a Phase 2b Trial of Dalcinonacog Alfa for the Treatment of Hemophilia B http://ir.catalystbiosciences.com/news-releases/news-release-details/catalyst-biosciences-initiates-phase-2b-trial-dalcinonacog-alfa Currently enrolling individuals with severe hemophilia B SOUTH SAN FRANCISCO, Calif. , April 02, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq:CBIO), today announced the initiation of enrollment in a Phase 2b study of dalcinonacog alfa (DalcA), a next-generation subcutaneously (SQ) Tue, 02 Apr 2019 08:00:00 -0400 Catalyst Biosciences, Inc. News Releases 12036 Catalyst Biosciences Receives Orphan Designation from the European Commission for Marzeptacog Alfa (Activated) http://ir.catalystbiosciences.com/news-releases/news-release-details/catalyst-biosciences-receives-orphan-designation-european Dosing successfully completed in the Phase 2 portion of the Phase 2/3 MarzAA trial for the treatment of hemophilia A or B with inhibitors SOUTH SAN FRANCISCO, Calif. , April 01, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq: CBIO) today announced that the European Commission has Mon, 01 Apr 2019 12:45:00 -0400 Catalyst Biosciences, Inc. News Releases 12026 Catalyst Biosciences Reports Fourth Quarter and Full-Year 2018 Operating & Financial Results and Provides a Corporate Update http://ir.catalystbiosciences.com/news-releases/news-release-details/catalyst-biosciences-reports-fourth-quarter-and-full-year-2018 Completed enrollment of the MarzAA SQ Phase 2 trial and demonstrated safety and clinical efficacy, with >90% reduction in bleeding Completed a full immunogenicity analysis for DalcA, plan to initiate a Phase 2b 28-day SQ trial in March 2019 SOUTH SAN FRANCISCO, Calif. Thu, 07 Mar 2019 08:00:00 -0500 Catalyst Biosciences, Inc. News Releases 12011 Catalyst Biosciences Announces Poster Presentation at the Association for Research in Vision and Ophthalmology Annual Meeting http://ir.catalystbiosciences.com/news-releases/news-release-details/catalyst-biosciences-announces-poster-presentation-association SOUTH SAN FRANCISCO, Calif. , March 06, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced the presentation of a poster, in collaboration with partner Wed, 06 Mar 2019 08:00:00 -0500 Catalyst Biosciences, Inc. News Releases 12006 Catalyst Biosciences Presents Updated Data from Its Phase 2/3 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors at the 12th Annual EAHAD Congress http://ir.catalystbiosciences.com/news-releases/news-release-details/catalyst-biosciences-presents-updated-data-its-phase-23-trial Results from the study demonstrate that subcutaneous MarzAA (FVIIa) significantly reduces both annualized bleed rate and the percentage of days with bleeding Enrollment in the Phase 2 portion of the trial is complete SOUTH SAN FRANCISCO, Calif. , Feb. Fri, 08 Feb 2019 08:00:00 -0500 Catalyst Biosciences, Inc. News Releases 11926 Catalyst Biosciences Announces Preclinical Proof-of-Concept Data of Gene Therapy Candidate CB 2679d-GT for the Treatment of Hemophilia B http://ir.catalystbiosciences.com/news-releases/news-release-details/catalyst-biosciences-announces-preclinical-proof-concept-data Results show a four-fold reduction in bleeding time for CB 2679d-GT and a three-fold improvement in clotting activity when compared with an AAV-encoding Padua vector Data presented at the 12 th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) SOUTH SAN Wed, 06 Feb 2019 08:00:00 -0500 Catalyst Biosciences, Inc. News Releases 11901